MIT researchers developed antibody-bottlebrush prodrug conjugates (ABCs) that dramatically increase drug loading on antibodies from a traditional max of eight to hundreds of molecules. This platform offers versatile payload options, including standard cytotoxins and low-potency chemotherapies, potentially reducing systemic toxicity while improving therapeutic efficacy. Their Nature Biotechnology publication highlights the conjugation technology enabling tailored drug-to-antibody ratios, promising improvements over current antibody-drug conjugates in oncology.